Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Oxford Biomedica PLC

Division of Oxford BioMedica PLC
www.oxfordbiomedica.co.uk

Latest From Oxford Biomedica PLC

Deal Watch: GSK Invests In Early-Stage Synthetic Lethality Programs At Ideaya

Pharma pays $100m up front and makes $20m equity investment for rights to three preclinical cancer programs. Plus more than 20 deal summaries, including COVID-19-related transactions.

Deal Watch: Chinook To Go Public Via Reverse Merger With Troubled Aduro

Focused on precision medicine for renal disease, Chinook gets Aduro’s Nasdaq listing and starting capital of $200m. During a wave of modest-sized M&A deals, Tetra finds buyer, Tetraphase gets competing bids.

Deals Business Strategies

Coronavirus Update: Novartis Joins Vaccine Efforts With Gene Therapy Approach

Having kept out of the race to develop a vaccine until now, Novartis has joined efforts with a collaboration using the AAV gene therapy vector.

Companies Coronavirus COVID-19

Oxford’s COVID-19 Vaccine Makers To Parallel Clinical Studies

An industry consortium will drive forward new manufacturing processes in parallel with the Oxford group’s COVID-19 vaccine clinical studies; these studies could produce Phase III efficacy results by this autumn.

Coronavirus COVID-19 Manufacturing
See All

Company Information

  • Industry
  • Biotechnology
    • Gene Therapy, Cell Therapy
    • Large Molecule
      • Antibodies
  • Pharmaceuticals
    • Drug Delivery
      • Macromolecule
    • Vaccines
  • Services
  • Therapeutic Areas
  • Cancer
  • Neurology, Nervous System
  • Ophthalmic
  • Alias(es)
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • Europe
      • Western Europe
        • UK
  • Parent & Subsidiaries
  • Oxford BioMedica PLC
  • Oxford Biomedica PLC
  • Senior Management
  • John Dawson, CEO
    Stuart Paynter, CFO
    Jason Slingsby, CBO
    Kyriacos Mitrophanous, CSO
    James Miskin, CTO
    Nick Page, COO
    Lisa Giles, Chief Project & Dev Officer
  • Contact Info
  • Oxford Biomedica PLC
    Phone: (44) 1865 783 000
    Windrush Court
    Transport Way
    Oxford, OX4 6LT
    UK
UsernamePublicRestriction

Register